BRIEF-Acadia Pharmaceuticals Provides Update On Regulatory Submission For Trofinetide For The Treatment Of Rett Syndrome In The European Union

Reuters

Feb 03

Feb 2 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O:

ACADIA PHARMACEUTICALS PROVIDES UPDATE ON REGULATORY SUBMISSION FOR TROFINETIDE FOR THE TREATMENT OF RETT SYNDROME IN THE EUROPEAN UNION
ACADIA PHARMACEUTICALS INC - RECEIVES NEGATIVE TREND VOTE ON TROFINETIDE MAA
ACADIA PHARMACEUTICALS INC - TO REQUEST RE-EXAMINATION OF CHMP OPINION

Source text: ID:nBw4c9N3xa

Further company coverage: ACAD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608890148"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608890148\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608890148?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 05:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608890148","market":"nz","top_or_hot":-1,"title":"BRIEF-Acadia Pharmaceuticals Provides Update On Regulatory Submission For Trofinetide For The Treatment Of Rett Syndrome In The European Union","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Acadia Pharmaceuticals Provides Update On Regulatory Submission For Trofinetide For The Treatment Of Rett Syndrome In The European Union</title></head><body><p><span>Feb 2 (Reuters)</span><span> - </span>ACADIA Pharmaceuticals Inc <span>ACAD.O</span>:</p><ul><li><p>ACADIA PHARMACEUTICALS PROVIDES UPDATE ON REGULATORY SUBMISSION FOR TROFINETIDE FOR THE TREATMENT OF RETT SYNDROME IN THE EUROPEAN UNION</p></li><li><p>ACADIA PHARMACEUTICALS INC - RECEIVES NEGATIVE TREND VOTE ON TROFINETIDE MAA</p></li><li><p>ACADIA PHARMACEUTICALS INC - TO REQUEST RE-EXAMINATION OF CHMP OPINION</p></li></ul><p>Source text: <span>ID:nBw4c9N3xa</span></p><p>Further company coverage: <span>ACAD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Acadia Pharmaceuticals Provides Update On Regulatory Submission For Trofinetide For The Treatment Of Rett Syndrome In The European Union</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Acadia Pharmaceuticals Provides Update On Regulatory Submission For Trofinetide For The Treatment Of Rett Syndrome In The European Union\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-03 05:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Acadia Pharmaceuticals Provides Update On Regulatory Submission For Trofinetide For The Treatment Of Rett Syndrome In The European Union</title></head><body><p><span>Feb 2 (Reuters)</span><span> - </span>ACADIA Pharmaceuticals Inc <span>ACAD.O</span>:</p><ul><li><p>ACADIA PHARMACEUTICALS PROVIDES UPDATE ON REGULATORY SUBMISSION FOR TROFINETIDE FOR THE TREATMENT OF RETT SYNDROME IN THE EUROPEAN UNION</p></li><li><p>ACADIA PHARMACEUTICALS INC - RECEIVES NEGATIVE TREND VOTE ON TROFINETIDE MAA</p></li><li><p>ACADIA PHARMACEUTICALS INC - TO REQUEST RE-EXAMINATION OF CHMP OPINION</p></li></ul><p>Source text: <span>ID:nBw4c9N3xa</span></p><p>Further company coverage: <span>ACAD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065170008.USD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA13Q8VJ:1","article_id":"2608890148","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608890148","pubTimestamp":1770066990,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Acadia Pharmaceuticals Provides Update On Regulatory Submission For Trofinetide For The Treatment Of Rett Syndrome In The European UnionFeb 2 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O:ACADIA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","BK4139":"生物科技","ACAD":"阿卡迪亚","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC"},"translate_title":"简介-Acadia Pharmaceuticals提供了欧盟用于治疗Rett综合征的曲非肽监管提交的最新信息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACAD":0.9},"content_text":"BRIEF-Acadia Pharmaceuticals Provides Update On Regulatory Submission For Trofinetide For The Treatment Of Rett Syndrome In The European UnionFeb 2 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O:ACADIA PHARMACEUTICALS PROVIDES UPDATE ON REGULATORY SUBMISSION FOR TROFINETIDE FOR THE TREATMENT OF RETT SYNDROME IN THE EUROPEAN UNIONACADIA PHARMACEUTICALS INC - RECEIVES NEGATIVE TREND VOTE ON TROFINETIDE MAAACADIA PHARMACEUTICALS INC - TO REQUEST RE-EXAMINATION OF CHMP OPINIONSource text: ID:nBw4c9N3xaFurther company coverage: ACAD.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}